Skip to Content

Emicizumab use while Breastfeeding

Drugs containing Emicizumab: Hemlibra

Medically reviewed by Drugs.com. Last updated on Nov 10, 2020.

Emicizumab Levels and Effects while Breastfeeding

Summary of Use during Lactation

No information is available on the clinical use of emicizumab during breastfeeding. Because emicizumab is a large protein molecule with a molecular weight of 145,600, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Substance Identification

Substance Name

Emicizumab

CAS Registry Number

1610943-06-0

Drug Class

  • Breast Feeding
  • Lactation
  • Antibodies, Monoclonal
  • Antineoplastic Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.